Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma

被引:44
作者
Bockhorn, M
Frilling, A
Rewerk, S
Liedke, M
Dirsch, O
Schmid, KW
Broelsch, CE
机构
[1] Univ Hosp Essen, Dept Gen & Transplantat Surg, D-45122 Essen, Germany
[2] Univ Hosp Essen, Dept Pathol, D-45122 Essen, Germany
[3] Univ Hosp Mannheim, Dept Gen Surg, Mannheim, Germany
关键词
D O I
10.1089/105072504323150813
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Medullary thyroid carcinoma (MTC) originates from C-cells. A wide variety of tumor markers including calcitonin (CT), carcinoembryonic antigen (CEA), and chromogranin A are produced by MTC. Surgery remains the only potentially curative therapy, and early detection of the primary remains the most important prognostic factor for a positive outcome for the patient. The following case concerns a 50-year-old woman with histologically proven MTC, who completely lacked serum elevation of both CT and CEA. Methods: We performed a total thyroidectomy with lymphadenectomy in the central compartment. Histologic sections were stained for CT, CEA, and chromogranin A. Additionally we examined the patient's blood for mutations in the RET proto-oncogene. Results: Serum CT and CEA were below the detection level in the serum. The tumor showed weak staining for CT, but strong staining for CEA and chromogranin A. Sequencing of the RET-protooncogene revealed no mutations. Five years after the operation, the patient remains well and shows no signs of tumor recurrence. Conclusions: We hereby report of a patient with neither plasma elevation of CT nor CEA. From the clinical standpoint, it is important to determine how this subgroup of MTC should be followed because CT and CEA are of no clinical use.
引用
收藏
页码:468 / 470
页数:3
相关论文
共 23 条
[1]  
Ball Douglas W., 1996, P946
[2]   Impact of chromogranin A measurement in the work-up of neuroendocrine tumors [J].
Baudin, E ;
Bidart, JM ;
Bachelot, A ;
Ducreux, M ;
Elias, D ;
Ruffié, P ;
Schlumberger, M .
ANNALS OF ONCOLOGY, 2001, 12 :S79-S82
[3]   Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner [J].
Bockisch, A ;
Brandt-Mainz, K ;
Görges, R ;
Müller, S ;
Stattaus, J ;
Antoch, G .
ACTA MEDICA AUSTRIACA, 2003, 30 (01) :22-25
[4]   The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer [J].
Brandt-Mainz, K ;
Müller, SP ;
Görges, R ;
Saller, B ;
Bockisch, A .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (05) :490-496
[5]  
BUSNARDO B, 1984, CANCER, V53, P278, DOI 10.1002/1097-0142(19840115)53:2<278::AID-CNCR2820530216>3.0.CO
[6]  
2-Z
[7]  
BUSNARDO B, 1980, P 2 INT S CALC HORM, P128
[8]   MUTATIONS IN THE RET PROTOONCOGENE ARE ASSOCIATED WITH MEN 2A AND FMTC [J].
DONISKELLER, H ;
DOU, SS ;
CHI, D ;
CARLSON, KM ;
TOSHIMA, K ;
LAIRMORE, TC ;
HOWE, JR ;
MOLEY, JF ;
GOODFELLOW, P ;
WELLS, SA .
HUMAN MOLECULAR GENETICS, 1993, 2 (07) :851-856
[9]  
Franke WG, 2000, ANTICANCER RES, V20, P5257
[10]   PRESYMPTOMATIC SCREENING FOR MEDULLARY-THYROID CARCINOMA IN PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A [J].
FRILLING, A ;
ROHER, HD ;
PONDER, BAJ .
WORLD JOURNAL OF SURGERY, 1994, 18 (04) :577-582